These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17329908)

  • 1. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant.
    Fujii Y; Takahashi M; Morita H; Kikuchi H; Aramaki Y; Amidon GL
    Drug Metab Pharmacokinet; 2007 Feb; 22(1):26-32. PubMed ID: 17329908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DX-9065a, a direct inhibitor of factor Xa.
    Kaiser B
    Cardiovasc Drug Rev; 2003; 21(2):91-104. PubMed ID: 12847561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
    Tobu M; Iqbal O; Ma Q; Schultz C; Jeske W; Hoppensteadt D; Lewis B; Fareed D; Fareed J
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):1-17. PubMed ID: 12643318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclodextrins improve oral absorption of a novel factor Xa inhibitor by interfering with interaction between the drug and bile acids in rats.
    Fujii Y; Takahashi M; Ishiguro T; Sakuma S; Uekama K; Irie T
    J Pharm Pharmacol; 2013 Nov; 65(11):1598-606. PubMed ID: 24118066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.
    Murayama N; Tanaka M; Kunitada S; Yamada H; Inoue T; Terada Y; Fujita M; Ikeda Y
    Clin Pharmacol Ther; 1999 Sep; 66(3):258-64. PubMed ID: 10511061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.
    Hara T; Yokoyama A; Ishihara H; Yokoyama Y; Nagahara T; Iwamoto M
    Thromb Haemost; 1994 Mar; 71(3):314-9. PubMed ID: 8029795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
    Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic additives in its oral dosage form.
    Fujii Y; Kanamaru T; Kikuchi H; Nakagami H; Yamashita S; Akashi M; Sakuma S
    Int J Pharm; 2011 Dec; 421(2):244-51. PubMed ID: 22001539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
    Alexander JH; Dyke CK; Yang H; Becker RC; Hasselblad V; Zillman LA; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Saint-Jacques H; Chetcuti S; Burton JR; Buergler JM; Spence FP; Shimoto Y; Robertson TL; Kunitada S; Bovill EG; Armstrong PW; Harrington RA;
    J Thromb Haemost; 2004 Feb; 2(2):234-41. PubMed ID: 14995984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.
    Becker RC; Alexander JH; Li Y; Robertson T; Kunitada S; Spencer FA; Yang H; Harrington RA
    J Thromb Thrombolysis; 2004 Dec; 18(3):193-7. PubMed ID: 15815881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
    Yamashita T; Tsuji T; Matsuoka A; Giddings JC; Yamamoto J
    Thromb Res; 1997 Jan; 85(1):45-51. PubMed ID: 8983124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the anticoagulant 14C-DX-9065a in the healthy male volunteer after a single intravenous dose.
    Murayama N; McMahon H; Young CG; McCracken NW; Okamura Y; Hakusui H; Tanaka M
    Xenobiotica; 2000 May; 30(5):515-21. PubMed ID: 10875684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
    Becker RC; Alexander JH; Dyke C; Huang Y; Saint-Jacques H; Hasselblad V; Harrington RA; Bovill EG;
    Thromb Res; 2006; 117(4):439-46. PubMed ID: 15882894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of Porphyromonas gingivalis growth by a factor Xa inhibitor, DX-9065a.
    Matsushita K; Imamura T; Tancharoen S; Tatsuyama S; Tomikawa M; Travis J; Potempa J; Torii M; Maruyama I
    J Periodontal Res; 2006 Jun; 41(3):171-6. PubMed ID: 16677284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood.
    Kaiser B; Jeske W; Walenga JM; Fareed J
    Blood Coagul Fibrinolysis; 1999 Dec; 10(8):495-501. PubMed ID: 10636461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats.
    Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
    Thromb Haemost; 1994 Sep; 72(3):392-6. PubMed ID: 7855790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.
    Yamaguchi Y; Okabe K; Liang J; Matsumura F; Ohshiro H; Ishihara K; Matsuda T; Takeya M; Kuratsu JI; Mori K; Yamada S; Ogawa M
    Dig Dis Sci; 1999 Dec; 44(12):2568-76. PubMed ID: 10630515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa.
    Matsushita K; Imamura T; Tomikawa M; Tancharoen S; Tatsuyama S; Maruyama I
    J Periodontal Res; 2006 Apr; 41(2):148-56. PubMed ID: 16499718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.